About this Journal Submit a Manuscript Table of Contents
Journal of Thyroid Research
Volume 2012 (2012), Article ID 618985, 12 pages
Review Article

Differentiated Thyroid Cancer: Management of Patients with Radioiodine Nonresponsive Disease

Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1461, Houston, TX 77030, USA

Received 1 August 2011; Revised 21 November 2011; Accepted 21 November 2011

Academic Editor: Mingzhao M. Xing

Copyright © 2012 Naifa Lamki Busaidy and Maria E. Cabanillas. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [23 citations]

The following is the list of published articles that have cited the current article.

  • Hala Ahmadieh, and Sami T. Azar, “Controversies in the Management and Followup of Differentiated Thyroid Cancer: Beyond the Guidelines,” Journal of Thyroid Research, vol. 2012, pp. 1–8, 2012. View at Publisher · View at Google Scholar
  • Natalie Burrows, Brian Telfer, Georg Brabant, and Kaye J. Williams, “Inhibiting the phosphatidylinositide 3-kinase pathway blocks radiation-induced metastasis associated with Rho-GTPase and Hypoxia-inducible factor-1 activity,” Radiotherapy and Oncology, vol. 108, no. 3, pp. 548–553, 2013. View at Publisher · View at Google Scholar
  • Sofia Tsirona, Varvara Vlassopoulou, Marinella Tzanela, Phoebe Rondogianni, George Ioannidis, Charalambos Vassilopoulos, Efthimia Botoula, Panagiotis Trivizas, Ioannis Datseris, and Stylianos Tsagarakis, “ Impact of early vs late postoperative radioiodine remnant ablation on final outcome in patients with low-risk well-differentiated thyroid cancer ,” Clinical Endocrinology, 2013. View at Publisher · View at Google Scholar
  • Hafiz Muhammad Ali, Andrei Maksimenko, Giorgia Urbinati, Hubert Chapuis, Mouna Raouane, Didier Desmaële, Hayashi Yasuhiro, Hideyoshi Harashima, Patrick Couvreur, and Liliane Massaad-Massade, “Effects of silencing RET/PTC1 oncogene in papillary thyroid carcinoma by siRNA-squalene nanoparticles with and without fusogenic companion GALA-Cholesterol,” Thyroid, pp. 130725184317009, 2013. View at Publisher · View at Google Scholar
  • Roger T. Anderson, John E. Linnehan, Vanita Tongbram, Lori J. Wirth, and Karen Keating, “Clinical, Safety, and Economic Evidence in Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Systematic Literature Review,” Thyroid, vol. 23, no. 4, pp. 392–407, 2013. View at Publisher · View at Google Scholar
  • Sahar Elzein, Abdulkhaled Ahmed, Eleanor Lorenz, and Sabapathy Prakash Balasubramanian, “Thyroid incidentalomas on PET imaging – Evaluation of management and clinical outcomes,” The Surgeon, 2014. View at Publisher · View at Google Scholar
  • Aaron B. Cohen, and Marcia S. Brose, “Second-Line Treatment for Advanced Thyroid Cancer: An Indication in Need of Randomized Clinical Trials,” Journal of Clinical Endocrinology & Metabolism, vol. 99, no. 6, pp. 1995–1997, 2014. View at Publisher · View at Google Scholar
  • Chengkun Wu, Jean-Marc Schwartz, Georg Brabant, and Goran Nenadic, “Molecular profiling of thyroid cancer subtypes using large-scale text mining,” Bmc Medical Genomics, vol. 7, 2014. View at Publisher · View at Google Scholar
  • Osamu Tohyama, Junji Matsui, Kotaro Kodama, Naoko Hata-Sugi, Takayuki Kimura, Kiyoshi Okamoto, Yukinori Minoshima, Masao Iwata, and Yasuhiro Funahashi, “Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models,” Journal of Thyroid Research, vol. 2014, pp. 1–13, 2014. View at Publisher · View at Google Scholar
  • M. Elise R. Graham, Robert D. Hart, Susan Douglas, Fawaz M. Makki, Devanand Pinto, Angela L. Butler, Martin Bullock, Matthew H. Rigby, Jonathan R. B. Trites, S. Mark Taylor, and Rama Singh, “Serum microRNA profiling to distinguish papillary thyroid cancer from benign thyroid masses,” Journal of Otolaryngology - Head & Neck Surgery, vol. 44, no. 1, 2015. View at Publisher · View at Google Scholar
  • Martijn R. Meijerink, Hester J. Scheffer, Remco de Bree, and Robert-Jan Sedee, “Percutaneous Irreversible Electroporation for Recurrent Thyroid Cancer—A Case Report,” Journal of Vascular and Interventional Radiology, vol. 26, no. 8, pp. 1180–1182, 2015. View at Publisher · View at Google Scholar
  • Maria E. Cabanillas, Martin Schlumberger, Barbara Jarzab, Rossella Elisei, Kate Newbold, Lisa F. Licitra, Steven I. Sherman, Douglas W. Ball, Duncan Topliss, Corina Andresen, James P. O'Brien, Min Ren, Yasuhiro Funahashi, Roger Allison, Renato G. Martins, Furio Pacini, Bruce Robinson, Judith C. McCaffrey, Manisha H. Shah, and Donald L. Bodenner, “A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment,” Cancer, 2015. View at Publisher · View at Google Scholar
  • Hannah A. Blair, and Greg L. Plosker, “Sorafenib: a review of its use in patients with radioactive iodine-refractory, metastatic differentiated thyroid carcinoma,” Targeted Oncology, vol. 10, no. 1, pp. 171–178, 2015. View at Publisher · View at Google Scholar
  • Martin Schlumberger, Makoto Tahara, Lori J. Wirth, Bruce Robinson, Marcia S. Brose, Rossella Elisei, Mouhammed Amir Habra, Kate Newbold, Manisha H. Shah, Ana O. Hoff, Andrew G. Gianoukakis, Naomi Kiyota, Matthew H. Taylor, Sung-Bae Kim, Monika K. Krzyzanowska, Corina E. Dutcus, Begoña de las Heras, Junming Zhu, and Steven I. Sherman, “Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer,” New England Journal of Medicine, vol. 372, no. 7, pp. 621–630, 2015. View at Publisher · View at Google Scholar
  • Seok-Mo Kim, Ki-Cheong Park, Jeong-Yong Jeon, Bup-Woo Kim, Hyeung-Kyoo Kim, Ho-Jin Chang, Seung-Hoon Choi, Cheong-Soo Park, and Hang-Seok Chang, “Potential anti-cancer effect of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a novel histone deacetylase inhibitor, for the treatment of thyroid cancer,” BMC Cancer, vol. 15, no. 1, 2015. View at Publisher · View at Google Scholar
  • Naomi Kiyota, Martin Schlumberger, Kei Muro, Yuichi Ando, Shunji Takahashi, Yasukazu Kawai, Lori Wirth, Bruce Robinson, Steven Sherman, Takuya Suzuki, Katsuki Fujino, Anubha Gupta, Seiichi Hayato, and Makoto Tahara, “Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer,” Cancer Science, 2015. View at Publisher · View at Google Scholar
  • Xiaobing Ye, Yiping Zhu, and Juan Cai, “Relationship between toxicities and clinical benefits of newly approved tyrosine kinase inhibitors in thyroid cancer: A meta-analysis of literature,” Journal Of Cancer Research And Therapeutics, vol. 11, no. 6, pp. C185–C190, 2015. View at Publisher · View at Google Scholar
  • Ateesha F. Mohamed, Juan Marcos González, and Angelyn Fairchild, “Patient Benefit-Risk Tradeoffs for Radioactive Iodine-Refractory Differentiated Thyroid Cancer Treatments,” Journal of Thyroid Research, vol. 2015, pp. 1–8, 2015. View at Publisher · View at Google Scholar
  • Pablo Mínguez, Glenn Flux, José Genollá, Alejandro Delgado, Emilia Rodeño, and Katarina Sjögreen Gleisner, “Whole-remnant and maximum-voxel SPECT/CT dosimetry in 131I-NaI treatments of differentiated thyroid cancer,” Medical Physics, vol. 43, no. 10, pp. 5279–5287, 2016. View at Publisher · View at Google Scholar
  • Tatiana Kelil, Abhishek R. Keraliya, Stephanie A. Howard, Katherine M. Krajewski, Marta Braschi-Amirfarzan, Jason L. Hornick, Nikhil H. Ramaiya, and Sree Harsha Tirumani, “Current Concepts in the Molecular Genetics and Management of Thyroid Cancer: An Update for Radiologists,” RadioGraphics, vol. 36, no. 5, pp. 1478–1493, 2016. View at Publisher · View at Google Scholar
  • R. A. Werner, K. Lückerath, J. S. Schmid, T. Higuchi, M. C. Kreissl, I. Grelle, C. Reiners, A. K. Buck, and C. Lapa, “Thyroglobulin fluctuations in patients with iodine-refractory differentiated thyroid carcinoma on lenvatinib treatment – initial experience,” Scientific Reports, vol. 6, pp. 28081, 2016. View at Publisher · View at Google Scholar
  • Anubha Gupta, Barbara Jarzab, Jaume Capdevila, Robert Shumaker, and Ziad Hussein, “Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer,” British Journal of Clinical Pharmacology, vol. 81, no. 6, pp. 1124–1133, 2016. View at Publisher · View at Google Scholar
  • James E. Frampton, “Lenvatinib: A Review in Refractory Thyroid Cancer,” Targeted Oncology, vol. 11, no. 1, pp. 115–122, 2016. View at Publisher · View at Google Scholar